Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

Novartis AG raised its outlook for the year after profit beat estimates in the first quarter, driven by medicines for breast ...

Novartis has today released a more optimistic full-year earnings forecast, citing the strong growth of drugs such as Leqvio, ...

Novartis raised its 2025 outlook after high demand for key drugs drove first-quarter profit and sales above expectations, becoming the first among peers to lift forecasts this quarter despite looming ...

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...